Docstoc

Aarkstore.com - Alzheimers Disease - Markets_ Pipeline and Opportunities 2009treatment

Document Sample
Aarkstore.com - Alzheimers Disease - Markets_ Pipeline and Opportunities 2009treatment Powered By Docstoc
					Aarkstore.com announces, a new market research report is available in its vast collection:


 Alzheimers Disease: Markets, Pipeline and Opportunities 2009
http://www.aarkstore.com/reports/Alzheimers-Disease-Markets-Pipeline-and-Opportunities-2009-
146429.html

Overview:

Todays armoury of approved drugs for the treatment of Alzheimers Disease (AD) largely depends on
just five therapeutic agents. In 2007, three of these agents represented 88% of global sales, in a
market that this report estimates exceeded $6 billion in 2008. There are presently no cures for AD,
and current drugs are only able to treat some of the symptoms in some people, with benefits that are
often short-lived. Hope is being placed in future disease-modifying drugs, but this report shows that
80% of these candidates are still at Phases I and II. With the relatively recent suspension of two
prominent potential disease-modifying Phase III candidates, immediate hopes for these kinds of new-
generation drugs now rest on just two to three late-stage candidates. Historically, efforts to develop
drugs to treat neurodegenerative disease have demonstrated significant risk, and failure rates have
been high. While this has focused companies’ efforts on targeting the underlying disease mechanisms,
alternative strategies have been stimulated by studies showing that some of the changes found in AD
mirror those seen in some other conditions. This report estimates that 30% of current Phase III trials
are investigating drugs already approved for other indications. A high proportion of Phase III studies
are also investigating new formulations of existing approved drugs or new drug combinations. The AD
market offers high growth potential, particularly as more effective treatments are developed. It is also
evident that therapeutic opportunities in this field are still wide open, as unmet medical need grows.
This report gives a comprehensive overview of the market performance of approved AD drugs,
globally, regionally and in the US. The current pipeline, drug development strategies and opportunities
in this field are also reviewed.

Alzheimers Disease:

In 2006 it was estimated that 27 million people globally were suffering from AD – a figure that is
expected to quadruple to more than 100 million by 2050, if a cure is not found. Direct and indirect
costs of AD and other dementias in the US are more than $148 billion annually, with worldwide costs
for dementia care estimated at $315 billion annually. The 2003 World Health Report indicated that
dementia contributed 11.2% of years lived with disability in people aged 60 years and older. This is
higher than strokes (9.5%), musculoskeletal disorders (8.9%), cardiovascular disease (5.0%) and all
forms of cancer (2.4%). Markets: The global AD drug market has grown steadily over the last decade,
from around $500 million in 1999 to over $6 billion in 2008, which is an average increase of more
than 33% per year. In the last five years, the average growth rate was 23%. Just five approved drugs
dominate global sales, three of which represented 88% of global sales in 2007.

Pipeline:

In contrast to the handful of approved drugs for the treatment of AD – where just five agents account
for an estimated 95%+ of drug sales – there are more than 178 candidate drugs or candidate
treatments currently in the clinical pipeline. Of these, 82% are at Phases I and II. In addition to drugs
aimed at targeting AD directly, more than 35 other drug classes are being investigated in an effort to
development other strategies for treating AD and its symptoms.

Table of Contents:
1. Alzheimer’s Disease 6
1.1 Alzheimer’s Disease
1.2 Statistics and Costs
1.3 Histopathology
1.4 Amyloid Beta (Aβ)
1.5 Tau Proteins and Neurofibrillary Tangles
1.6 Cholinergic Hypothesis
1.7 Diagnosis
1.8 Cognitive Tests
1.9 Treatment

2. Alzheimer’s Disease Statistics 14
2.1 Background
2.2 Dementia - Global Population
2.3 Global Incidence
2.4 Global New Cases
2.5 Global Prevalence
2.6 Estimated Global Prevalence in 2020
2.7 Developed and Developing Countries
2.8 Global Trends
2.9 Dementia and AD
2.10 John Hopkins University Study
2.11 Disease Costs

3. The Global Drug Market 23
3.1 The Global Drug Market

4. Donepezil Hydrochloride (Aricept®) 24
4.1 Donepezil hydrochloride (Aricept®)
4.2 Global Sales
4.3 Global Sales - Eisai
4.4 Japan Sales - Eisai
4.5 US Sales - Eisai
4.6 Regional Sales – Eisai
4.7 Global Sales - Pfizer

More Related Reports :

 Biomarkers in Parkinsons Disease, 2011

 Biomarkers in Breast Cancer, 2011

 Stroke: Competing Treatments and Market Entry Considerations

 Neuropathic Pain: Competing Treatments and Market Entry Considerations

 Hypertension: Competing Treatments and Market Entry Considerations

 Alzheimers Disease: Competing Treatments and Market Entry Considerations

 Targeting Cancer Stem Cells: Therapeutic Strategies, Pipeline, Biomarkers and Opportunities

 Peripheral Neuropathy and Neuropathic Pain, 2008: Current, pipeline and emerging drugs for the
treatment of peripheral neuropathy and neuropathic pain

 Alzheimers Disease: Markets, Pipeline and Opportunities 2009

 Cancer Drug Resistance

 Antibiotics and Drug Resistance 2008


For More details about above & other Reports plz contact :

Vina

Aarkstore.com

Contact: Marketing team

Mob.No.918149852585

Email: enquiry@aarkstore.com

URL: http://www.aarkstore.com/

http://in.linkedin.com/in/aarkstore

http://www.facebook.com/aarkstore

http://www.aarkwebsolutions.com/

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:3
posted:2/19/2013
language:Unknown
pages:3